These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 34932189)

  • 1. Validation of HER2 Status in Whole Genome Sequencing Data of Breast Cancers with the Ploidy-Corrected Copy Number Approach.
    Wojtaszewska M; Stępień R; Woźna A; Piernik M; Sztromwasser P; Dąbrowski M; Gniot M; Szymański S; Socha M; Kasprzak P; Matkowski R; Zawadzki P
    Mol Diagn Ther; 2022 Jan; 26(1):105-116. PubMed ID: 34932189
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Landscape of somatic allelic imbalances and copy number alterations in HER2-amplified breast cancer.
    Staaf J; Jönsson G; Ringnér M; Baldetorp B; Borg A
    Breast Cancer Res; 2011; 13(6):R129. PubMed ID: 22169037
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Longitudinal HER2 amplification tracked in circulating tumor DNA for therapeutic effect monitoring and prognostic evaluation in patients with breast cancer.
    Guan X; Liu B; Niu Y; Dong X; Zhu X; Li C; Li L; Yi Z; Sun X; Chen H; Lu S; Ma F
    Breast; 2020 Feb; 49():261-266. PubMed ID: 31927339
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Next-generation assessment of human epidermal growth factor receptor 2 gene (ERBB2) amplification status in invasive breast carcinoma: a focus on Group 4 by use of the 2018 American Society of Clinical Oncology/College of American Pathologists HER2 testing guideline.
    Hoda RS; Bowman AS; Zehir A; Razavi P; Brogi E; Ladanyi M; Arcila ME; Wen HY; Ross DS
    Histopathology; 2021 Mar; 78(4):498-507. PubMed ID: 32841416
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of Next Generation Sequencing for Detecting HER2 Copy Number in Breast and Gastric Cancers.
    Niu D; Li L; Yu Y; Zang W; Li Z; Zhou L; Jia L; Rao G; Gao L; Cheng G; Ji K; Lin D
    Pathol Oncol Res; 2020 Oct; 26(4):2577-2585. PubMed ID: 32621174
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Precise ERBB2 copy number assessment in breast cancer by means of molecular inversion probe array analysis.
    Christgen M; van Luttikhuizen JL; Raap M; Braubach P; Schmidt L; Jonigk D; Feuerhake F; Lehmann U; Schlegelberger B; Kreipe HH; Steinemann D
    Oncotarget; 2016 Dec; 7(50):82733-82740. PubMed ID: 27716627
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lack of independent prognostic and predictive value of centromere 17 copy number changes in breast cancer patients with known HER2 and TOP2A status.
    Nielsen KV; Ejlertsen B; Møller S; Jensen MB; Balslev E; Müller S; Knoop A; Mouridsen HT
    Mol Oncol; 2012 Feb; 6(1):88-97. PubMed ID: 22153616
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Next-Generation Assessment of Human Epidermal Growth Factor Receptor 2 (ERBB2) Amplification Status: Clinical Validation in the Context of a Hybrid Capture-Based, Comprehensive Solid Tumor Genomic Profiling Assay.
    Ross DS; Zehir A; Cheng DT; Benayed R; Nafa K; Hechtman JF; Janjigian YY; Weigelt B; Razavi P; Hyman DM; Baselga J; Berger MF; Ladanyi M; Arcila ME
    J Mol Diagn; 2017 Mar; 19(2):244-254. PubMed ID: 28027945
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genomic Copy Number Analysis of HER2-Equivocal Breast Cancers.
    Geiersbach KB; Willmore-Payne C; Pasi AV; Paxton CN; Werner TL; Xu X; Wittwer CT; Gulbahce HE; Downs-Kelly E
    Am J Clin Pathol; 2016 Oct; 146(4):439-47. PubMed ID: 27614666
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Somatic mutations and copy number variations in breast cancers with heterogeneous HER2 amplification.
    Van Bockstal MR; Agahozo MC; van Marion R; Atmodimedjo PN; Sleddens HFBM; Dinjens WNM; Visser LL; Lips EH; Wesseling J; van Deurzen CHM
    Mol Oncol; 2020 Apr; 14(4):671-685. PubMed ID: 32058674
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HER2, chromosome 17 polysomy and DNA ploidy status in breast cancer; a translational study.
    Halilovic A; Verweij DI; Simons A; Stevens-Kroef MJPL; Vermeulen S; Elsink J; Tops BBJ; Otte-Höller I; van der Laak JAWM; van de Water C; Boelens OBA; Schlooz-Vries MS; Dijkstra JR; Nagtegaal ID; Tol J; van Cleef PHJ; Span PN; Bult P
    Sci Rep; 2019 Aug; 9(1):11679. PubMed ID: 31406196
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Change in HER2 (ERBB2) gene status after taxane-based chemotherapy for breast cancer: polyploidization can lead to diagnostic pitfalls with potential impact for clinical management.
    Valent A; Penault-Llorca F; Cayre A; Kroemer G
    Cancer Genet; 2013; 206(1-2):37-41. PubMed ID: 23313108
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of HER2 status in invasive breast cancers with increased centromere 17 copy number.
    Jang MH; Kim EJ; Kim HJ; Chung YR; Park SY
    Breast Cancer Res Treat; 2015 Aug; 153(1):67-77. PubMed ID: 26223814
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Integrated Analysis of HER2 Copy Number by Cytogenomic Microarray in Breast Cancers With Nonclassical In Situ Hybridization Results.
    Haskell GT; Liu YJ; Chen H; Chen B; Meyer RG; Yuhas JA; Geiersbach KB
    Am J Clin Pathol; 2018 Jan; 149(2):135-147. PubMed ID: 29385416
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HER2 overexpression in urothelial carcinoma with GATA3 and PPARG copy number gains.
    Zhu X; Chan E; Turski ML; Mendez CE; Hsu SC; Kumar V; Shipp C; Jindal T; Chang K; Onodera C; Devine WP; Grenert JP; Stohr BA; Ding CC; Stachler MD; Quigley DA; Feng FY; Chu CE; Porten SP; Chou J; Friedlander TW; Koshkin VS
    Oncologist; 2024 Aug; 29(8):e1094-e1097. PubMed ID: 38908022
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti-HER2 targeted therapies.
    Ross JS; Gay LM; Wang K; Ali SM; Chumsri S; Elvin JA; Bose R; Vergilio JA; Suh J; Yelensky R; Lipson D; Chmielecki J; Waintraub S; Leyland-Jones B; Miller VA; Stephens PJ
    Cancer; 2016 Sep; 122(17):2654-62. PubMed ID: 27284958
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Determining true HER2 gene status in breast cancers with polysomy by using alternative chromosome 17 reference genes: implications for anti-HER2 targeted therapy.
    Tse CH; Hwang HC; Goldstein LC; Kandalaft PL; Wiley JC; Kussick SJ; Gown AM
    J Clin Oncol; 2011 Nov; 29(31):4168-74. PubMed ID: 21947821
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted next-generation sequencing enables reliable detection of HER2 (ERBB2) status in breast cancer and provides ancillary information of clinical relevance.
    Pfarr N; Penzel R; Endris V; Lier C; Flechtenmacher C; Volckmar AL; Kirchner M; Budczies J; Leichsenring J; Herpel E; Noske A; Weichert W; Schneeweiss A; Schirmacher P; Sinn HP; Stenzinger A
    Genes Chromosomes Cancer; 2017 Apr; 56(4):255-265. PubMed ID: 27792260
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Whole genome sequencing of HER2-positive metastatic extramammary Paget's disease: a case report.
    Lim BY; Guo Z; Lim JQ; Ko TK; Lee ECY; Kannan B; Lee JY; Lim AH; Li Z; Ng CC; Busmanis I; Chan JY
    Orphanet J Rare Dis; 2024 Jun; 19(1):223. PubMed ID: 38831459
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Assessment and significance of human epidermal growth factor receptor 2 gene status in breast cancer with polysomy of chromosome 17].
    Zhang H; Si JW; Zhang S; Wang Y; Li D; Li T
    Zhonghua Zhong Liu Za Zhi; 2016 Feb; 38(2):124-9. PubMed ID: 26899332
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.